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Abstract
The ability to trigger the degradation of polymeric nanoparticles (NPs) by a specific
stimulus can provide a

method

of

improved

drug

targeting

and

selective

release capabilities in vivo. The challenge for most polymeric drug delivery systems
remains the necessity for many stimuli events to trigger the release of cargo. Polymeric
nanotechnology containing “self-immolative polymers” looks to alleviate the reliance
on high concentrations of stimuli by undergoing complete end-to-end depolymerization
via a single stimulus-mediated reaction of an end-cap. Herein, NPs were developed using
poly(ethyl glyoxylate) (PEtG) blended with poly(D,L-lactic acid) (PLA) to encapsulate a
hydrophobic cargo to be released upon stimulus-triggered cleavage of the PEtG endcap. The PEtG-PLA NPs were formed using an oil-in-water emulsion-evaporation
technique. Particles

responsive

to stimuli including UV-light

and

reducing

conditions were prepared and studied. Cleavage of the end-caps of these polymers was
accomplished by introducing the relevant stimuli, resulting in a rapid degradation of the
particles and subsequent release of cargo. Nile red as a fluorescent probe and the
drug celecoxib were encapsulated within the particles and were shown to be released
upon introduction of small amounts of the appropriate stimulus. Initial cell culture studies
were performed to investigate the behavior of the systems in vitro. This system provides
the ability to tune the responsiveness of the NPs by simply changing the PEtG endcap, making them a great prospect for stimuli-responsive drug delivery vehicles.

Keywords
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Introduction

Polymers are a versatile class of materials which can be produced on industrial scales and
their properties can be easily tuned for a wide array of applications. The synthesis and
manufacturing of polymeric materials increased as the realization of their versatility in a
broad range of products became apparent. These ubiquitous materials emerged in the
early 1900’s and found applications in many industries including rubber, plastic,
petrochemical, packaging, agriculture, and pharmaceuticals (Figure 1).

Figure 1. Historical breakthroughs in the field of polymeric materials.

With the discovery of polystyrene and polypropylene, the world began producing
hundreds of tons of plastic every year.1, 2 Synthetic rubbers were already in production
by the 50’s with production of just under one million tons per year. By 2016, over 300
million tons of plastic and 26 million tons of rubber were produced worldwide.3
Synthetic polymers have led to a plethora of versatile materials and inventions that have
shaped today’s society. The inherent properties of polymers make them adaptable
materials. As one small change is made to a monomer, this change can be propagated
through the polymer chain resulting in an overall polymer with starkly different physical
and chemical properties. Because of their sensitivity to minute changes in their monomer
structures, polymers have highly tunable physical and chemical properties that can be
readily manipulated either chemically by altering the monomer structure, or by blending
with plasticizers and other polymers. The versatility of polymers allows scientists to
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create polymeric systems and materials with a wide array of applications from everyday
commercial products to highly advanced drug delivery systems (DDS).4
There exist many benefits to polymers; however, there remains the problem of how to
dispose of these materials once used. The majority of waste generated from plastics and
petrochemicals is non-compostable and nondegradable and accounts for over 10% of
total municipal waste.5 Incineration of these materials can release pollutants into the
atmosphere and recycling methods have proved to be costly and relatively inefficient.
The high stability, low solubility, potential toxicity and sheer volume make these
polymers difficult and expensive to dispose of efficiently.6 To address these critical
issues, degradable polymers that can exhibit the desirable properties of traditional
nondegradable polymers have emerged.2

1.1 Degradable Polymers
As attention has shifted towards decreasing waste buildup and toxic degradation products
of synthetic polymers, the focus has turned to the development of non-toxic, degradable
polymers without sacrificing too many of the desirable characteristics of traditional
plastics such as structural strength or durability.7 Synthetic polymers can be divided into
two major categories based on the chemical composition of their backbone: polymers
with heteroatom-containing backbones and polymers with only carbon-containing
backbones.8 Polymers with only carbon-containing backbones consist of carbon-carbon
bonds throughout the backbone of the macromolecule while polymers with heteroatomcontaining backbones offer the advantage of having atoms other than carbon in the main
chain backbone. Heteroatoms commonly used in these polymers include phosphorous
(polyphosphoesters, e.g., 1.1), nitrogen (polycaprolactam, e.g., 1.2), and oxygen
(poly(ethylene glycol), e.g., 1.3) (Figure 2).

1.1

1.2

1.3

Figure 2. Examples of polymers with heteroatom-containing backbones.
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While carbon-carbon bonded polymers yield very stable and relatively inert backbones,
heteroatoms introduce polarity into the polymer backbone which can be exploited for
chemical cleavage reactions.9 Traditional rubbers and plastics are composed of carbonchain polymers i.e. polybutadiene (1.4), polystyrene (1.5), polypropylene (1.6), and
poly(vinyl chloride) (PVC, 1.7) as shown in Figure 3.

1.4

1.5

1.6

1.7

Figure 3. Examples of polymers with only carbon in their backbone.

The polymers in Figure 3 are very durable and inert materials. The introduction of
heteroatoms, however, introduces potential areas to exploit for cleavage of the backbone
leading to erosion and degradation of the material. For example, inserting oxygen atoms
throughout the polymer backbone leads to a polyether. While the ether functional group
is quite stable and exhibits low chemical reactivity, their polar bonds can be cleaved by
the introduction of strong acids.10

1.1.1

Polyesters

Over the past three decades, research has yielded a vast library of degradable materials
with wide-scope applications into many fields including pharmaceutics, agriculture,
tissue engineering and commodities.11, 12 Current degradable polymers include polyesters,
polyacetals,

polyamides,

polyanhydrides,

polyphosphazenes,

polysulphones,

polysiloxanes, polyurethanes and polydisulfides. In each of these cases, a heteroatom
exists in the polymer backbone which leaves the polymer susceptible to cleavage
reactions. Of all the different functional groups of degradable polymers, polyesters have
been the most studied because they can be tailored to exhibit desirable properties
including biocompatibility and biodegradability.8 These properties will be discussed in
more detail below.
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In the early 1950’s reports of the first synthetic degradable polyesters, such as
polydioxanone (1.8), poly-3-hydroxyalkanoate (1.9), polyvalerolactone (1.10), and
polycaprolactone (PCL, 1.11) were reported for applications in the plastic industry
(Figure 4).4 The hydrolysable ester groups throughout these polymer backbones increase
the polymer’s susceptibility to degradation, significantly increasing their degradation
rates. The problem continues to be that these materials are not as cost effective for large
scale production as the more commonly used polymers such as high-density
polyethylene, low density polyethylene and polypropylene.

Figure 4. Common degradable polyesters.

An important feature of degradable polymers to consider is their biocompatibility. There
exists a subset of degradable polymers that are not only degradable, but also display
biodegradability - a feature defined as polymers that can be cleaved and degraded using
biological machinery. Biodegradable polymers have backbone linkages that can be
cleaved either by hydrolysis and/or enzyme-mediated within an organism.13 The majority
of biodegradable polymers currently in use are polyesters, including PCLs, poly(glycolic
acid) (PGA, 1.12), poly(D,L-lactic acid) (PLA, 1.13) and poly(L-lactic acid). Variations of
these homopolymers along with a variety of blends and copolymers (1.14) of these
polyesters have been synthesized and proven to afford biodegradability. Figure 5 shows
the most common polyesters used in medical applications. Applications of these
polymers have been reported in medical devices, tissue engineering scaffolds, and drug
delivery vehicles.14-16

Figure 5. The most common biodegradable polyesters for medical applications.
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While many of these materials have proved to be of great benefit, there still exist some
limitations inherent to the degradation process of common degradable polymers.
Degradable polymers rely on many chain scission cleavage events to slowly break down
the long polymer chains into shorter fragments. Over time, this process leads to a
complete degradation of the polymer. The degradation time of the polymer can be tuned
by manipulating the properties of the polymer either chemically or by mixing one
polymer with another to form a blend. However, the degradation of these polymers still
includes some inherent randomness or uncontrollable processes.17 Polyesters degrade by
many hydrolysis events of the ester linkages throughout the backbone. The overall rate
may be tuned to some degree, but the user has no control over where and when
hydrolysis occurs throughout the backbone. The process of degradation is simply random
in nature leaving little control as to specific ester bond cleavages. While polyesters and
other biodegradable polymers have made a big impact in healthcare and pharmaceutics,
there remain some limitations to these polymeric systems that could potentially be
improved upon.
In recent years, the evolution of degradable polymers has lead research towards polymers
that are not just degradable, but degradable upon introduction of a specific stimulus. The
question of how to gain control over the degradation process was addressed with the
emergence of self-immolative polymers (SIPs).18

1.2 The Development of Self-Immolative Polymers
1.2.1

Stimuli-Responsive Polymers

To overcome the lack of control in degradation of common degradable polymeric
materials, attention has moved to the development of stimuli-responsive polymers.
Stimuli-responsive polymers exhibit triggerable degradability upon exposure to a specific
stimulus. These polymers are synthesized with functional groups that have an inherent
sensitivity to certain conditions such as reduction/oxidation chemistry or acid/base
chemistry. These polymers show responsiveness when exposed to a specific stimulus that
will ultimately lead to their degradation. Specific polymers developed for this purpose
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include polyacetals, polydisulfides (1.15), poly(ortho esters) (1.16), polyketals (1.17) and
others. (Figure 6).19

1.15

1.16

1.17

Figure 6. Common stimuli-responsive polymers.

Stimuli-responsive polymers can give rise to materials that exhibit sensitivity to pH
(1.17), reduction (1.15) and temperature (1.16). Other stimuli-responsive polymers exist
that show responsive behavior to a variety of other factors including humidity,
wavelength or intensity of light, and magnetic fields. The physical response from these
polymers can be a variety of changes such as altering solubility, color, transparency,
conductivity or shape.20,

21

However, not all of these classes of stimuli-responsive

polymers are useful in applications where degradable polymers are required.
The introduction of stimuli-responsive polymers gives the user a more “degrade-ondemand” property to these polymers, but similar to the limitation of polyesters, stimuliresponsive polymers require many stimulus events to completely degrade the backbone.
Therefore, these polymers can only be used in situations where stimulus is plentiful. It
wasn’t until the emergence of “self-immolative” molecules that scientists could begin to
control specific stimulus-bond cleavage interactions.

1.2.2

Self-Immolative Small Molecules

A self-immolative system contains a stable bond between protecting and leaving groups
(LGs) which becomes labile upon activation leading to a “triggerable” release of the
LG.22 In 1981, Katzenellenbogen and coworkers introduced the first self-immolative
spacer into a prodrug delivery system.23

The spacer was based on p-aminobenzyl

alcohol, which could undergo a 1,6 elimination reaction to release a LG. This reaction
was protected with a triggerable protecting group (PG) on the amine and the drug was
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attached through a carbonate bond to the alcohol. With proper stimulus, the aromatic
amine can be exposed to undergo the elimination step, releasing the drug (Scheme 1).

Scheme 1. 1,6-elimination mechanism of p-aminobenzyl ester (Nu = nucleophile).
The purpose of introducing a spacer between the concealed drug and the PG was to
increase the distance between the bulky drug and the PG. Having the bulky drug close to
the PG was shown to reduce the enzymatic cleavage rate of some prodrugs.
Katzenellenbogen showed by introducing a self-immolative linker between the two
molecules lead to increased enzymatic cleavage due to reduced steric hindrance. Many
variations of this 1,6-elimination linker have been developed by using aromatic amine,
hydroxyl or thiol moieties, each undergoing a 1,6-elimination reaction.24
While the use of prodrugs has led to promising applications in therapeutics, the inherent
limiting factor to these types of systems is the continual need of stimulus to release drug.
For each equivalent of drug released, there needs to be an equal equivalent of stimulus
events. This limits the scope of potential PG that could be used for triggered removal of
prodrugs. In certain situations, where specific stimuli concentrations are low, it would be
beneficial to have a system in which one triggering event could lead to many equivalents
of drug to be released. The combined work of these early reports of self-immolative
molecules laid the groundwork for more promising macromolecular structures.

1.2.3

Self-Immolative Macromolecules

The invention of self-immolative linkers led to an expansive idea of combining several of
these linkers successively to create macromolecular structures.25 Self-immolative
oligomers and dendrimers were introduced in the early 2000’s. These macromolecular
structures were developed in an attempt to amplify responsiveness of self-immolative
linkers to stimuli. Self-immolative oligomers consist of several linkers covalently bonded
together, typically as dimers or trimers. Self-immolative dendrimers are composed of
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repeated branches that are organized in concentric layers called “generations” around a
central core or focal point.26 Both have been investigated for applications in drug
delivery.
In 2001, Scheeren and coworkers published the first self-immolative oligomer consisting
of derivatives of naphthyl and biphenyl moieties that underwent a cascade elimination
mechanism similar to that of the earlier aminobenzyl alcohols (Scheme 2a).27 These
linkers, along with p-aminobenzyl alcohol linker, can be successively bonded together by
carbamate bonds into oligomers. The terminal amine can be deprotected, resulting in
successive 1,10-elimination decarboxylation reactions to release a LG (Scheme 2b).

Scheme 2. (a) 1,8-elimination mechanism of a naphthyl-based linker and (b) 1,10-elimination
mechanism of a biphenyl-based linker.

Unfortunately, it was shown that the naphthyl and biphenyl systems failed to undergo the
hypothesized elimination cascades. It was hypothesized the energetic cost in
dearomatizing the systems in the 1,8- and 1,10-eliminations were too high to achieve a
rapid reaction. The aminobenzyl alcohol oligomer, however, could successfully undergo
consecutive elimination decarboxylation mechanisms to release a payload. The ratio to
stimulus events to molecules of cargo released in these systems is still 1:1, but it laid the
ground work for future linear and dendritic systems for signal amplification.
In 2008, Kratz developed the first self-immolative oligomer system that showed
increased drug release rates by amplification of stimulus.28 Kratz’s oligomer was based
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on a similar 1,6-elimination mechanism as above, but the model drug was also
conjugated to the aromatic moieties such that they could be released via 1,4-elimination
reactions. The stimulus could be amplified in this system due to multiple molecules of
model drug being released for one deprotection reaction (Scheme 3). Three equivalents of
a carbamate-linked cargo moiety could be released upon a single stimulus event.

Scheme 3. A self-immolative oligomer capable of 1,6-eliminations through its backbone and
1,4-eliminations of pendant groups.

As the development of self-immolative oligomers continued, another class of selfimmolative macromolecular structures were being investigated. In 2003, the first selfimmolative dendrimeric system was reported by McGrath and coworkers.26 A dendrimer
consists of repeated branches organized into layers all stemming from a common focal
point. McGrath’s group used a 2,4-bis(hydroxymethyl)phenol monomer with each
generation linked in succession (Scheme 4). Through cleavage of an allyloxybenzyl ether
group at the focal point, the cascade elimination that followed released four nitrophenol
molecules.
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Scheme 4. Example of 2,4-bis(hydroxymethyl)phenol-based dendrimer.
Once again, the self-immolative nature of this system relied on an elimination cascade
that propagates through several conjoined fragments to eliminate a cargo molecule. The
major advantage to dendrimeric systems is their amplification of the stimulus. With
McGrath’s early dendrimer, one stimulus event at the focal point allyl ether led to the
release of four equivalents of cargo molecule, p-nitrophenol. However, the difficulty
surrounding dendrimers is their cumbersome synthesis procedures. In addition, the
number of generations eventually reaches a maximum due to steric hindrance, leading to
a limit in how much cargo can be conjugated and released.
Dendrimeric structures continue to be investigated as drug delivery vehicles with
promising properties.25,

26, 29

With the development of self-immolative oligomers and

dendrimers in place, the next logical step was to investigate SIPs as potential stimuliresponsive materials.

1.2.4

Self-Immolative Polymers

SIPs are able to amplify a polymer’s sensitivity to a stimulus by only requiring a single
stimulus event to initiate a spontaneous chain depolymerization reaction.30 These
polymers can be stabilized by protecting their ends with a stimuli-responsive small
molecule. This is called “end-capping”. Once a SIP has been properly end-capped, it can
then be handled under ambient conditions without significant degradation (Figure 7).
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However, cleavage of the end-cap results in end-to-end depolymerization by a cascade of
reactions.

Figure 7. End-capped stabilized SIP subjected to end-cap cleavage followed by
depolymerization.

Small molecules used to end-cap polymers that show specific stimuli-responsive behavior
are termed stimuli-responsive end-caps. End-caps have shown sensitivity to a range of
stimuli including chemical, ultraviolet (UV) light, pH, temperature and redox potential.30,
31

In each case, the stimulus triggers a specific chemical reaction at the end-cap leading to

detachment from the polymer. The polymer, no longer protected, undergoes a rapid endto-end depolymerization.
To date there are two subclasses of SIPs that are distinguished by the mechanism that
governs their depolymerization. The first class of SIPs spontaneously degrade into
products that are different from the monomers used to synthesize the polymer.32,

33

Depolymerization is favored and happens spontaneously due to the stability of the
degradation products. The second class of SIPs is governed by the polymer’s low ceiling
temperature (Tc). Upon cleavage of these stimuli-responsive end-caps, entropy drives
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depolymerization of the polymer back to monomer units.34 This phenomenon can be
better understood by examining thermodynamics of polymerizations.
From the Gibbs free energy equation, the free energy of a polymerization reaction is the
sum of both the enthalpic and entropic contributions (eq. 1).
ΔG = ΔH – TΔS

eq. 1

ΔG = ΔH – TΔS = 0

eq. 2

T = ΔH/ΔS = Tc

eq. 3

For a given monomer with a set concentration, the enthalpy and entropy are fixed and
specific to that monomer. Therefore, the only variable that can be manipulated is the
temperature. An appropriate temperature must be found to make ΔG negative giving a
spontaneous reaction of monomers into polymer. Furthermore, there must exist a
temperature where ΔG = 0 (eq. 2) and the system is in equilibrium. In other words, the
rate of polymerization is equivalent to the rate of depolymerization.

At ΔG = 0,

temperature can be calculated by the ratio of ΔH and ΔS (eq. 3). This is called the
polymer’s Tc. At temperatures above a polymer’s Tc, the rate of depolymerization is
faster than the rate of polymerization. Conversely, at temperatures below the Tc of a
polymer, the rate of polymerization is faster than the rate of depolymerization. This
principle can also be represented graphically (Figure 8).35

Figure 8. Rates of depolymerization and polymerization as a function of temperature. They
intersect at the Tc.
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The second class of SIPs takes advantage of polymers with lower than ambient Tc. The
monomers are first polymerized below their Tc, allowing for the growth of long chains.
Then, before the material is allowed to warm, the ends of the polymer chains are capped
with a stimuli-responsive small molecule to trap the polymer chains and stabilize the
system. The material can then be warmed to temperatures higher than the Tc and can be
manipulated for different applications. When this material is subjected to its responsive
stimulus at ambient temperatures, the stabilizing end-cap substituents are removed and
the material spontaneously degrades.36 The major advantage to SIPs is their ability to
amplify the response to a stimulus. One cleavage event at a polymer end-cap leads to
complete end-to-end depolymerization of the entire polymer chain. In 2008, Shabat
reported the first SIP, which belongs to the first class of SIPs. The Shabat polmyer
consisted

of

a

polycarbamate

bis(trimethylsilyl)acetamide-responsive

backbone
end-cap,

that

upon

underwent

removal
a

of

the

domino-like

1,6-

elimination-decarboxylation cascade, resulting in complete degradation of the
macromolecule into carbon dioxide and azaquinone methide (Scheme 5).18 Altering the
sensitivity of the end-caps to a variety of stimuli yielded a material that could be
triggered to degrade in response to different triggers. The versatility of these materials
has provided efficacy in a multitude of areas including drug delivery, bio-sensors,
agriculture, and consumer products.37-40
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Scheme 5. Degradation mechanism of a polycarbamate-based SIP.
In 2009, Dewit and Gillies reported another carbamate-based SIP that degraded through
alternating intramolecular cyclization and 1,6-elimination reactions (Scheme 6).41 The
backbone consisted of alternating N,N’-dimethylethylenediamine and 4-hydroxybenzyl
alcohol units linked through carbamate bonds. A tert-butylcarbamate (Boc) group was
used to protect the terminal amine as a model end-cap. The polycarbamate was stable in
aqueous solution, but upon removal of the Boc group from the amine, an intramolecular
cyclization revealed the phenol to undergo a 1,6-elimination followed by a
decarboxylation to yield a consecutive free amine. The cascade continued from end-toend until the polymer completely degraded into N,N’-dimethylimidazolidinone, CO2, and
4-hydroxybenzyl alcohol products. The intramolecular cyclization step was the slower,
rate determining step in the degradation mechanism. In follow-up work, the insertion of
different cyclization reactions was used to tune the rate of depolymerization.42
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Scheme 6. Cyclization depolymerization mechanism of a SIP.
Phillips furthered the versatility of the SIP backbones by developing a polyacetal SIP
based on phthalaldehyde (Scheme 7).43 This backbone belongs to the second class of
SIPs, with degradation governed by the low Tc. By using a chloroformate derivative of 6nitroveratrole, a polyphthalaldehyde-based SIP that exhibited responsivity to UV light
was produced.

His group later showed this polymer was capable of forming

microparticles that could be triggered to release a cargo upon introduction of UV
light.44,45 Due to the low Tc of polyphthalaldehyde (PPHA), polymerization of the
dialdehyde was carried out at -78 °C. The end-cap reaction of terminal hemiacetal was
conducted before the material was allowed to warm to room temperature. They also
proved control over molecular weights by correlating the Mn to the concentration of the
initiator. At ambient temperatures, just 30 minutes of UV radiation reduced the weight
percent (wt%) of polymer coatings by 90%.

Scheme 7. Degradation mechanism of polyphthalaldehyde.
While the above backbones are promising and in further development, the degradation
products of these SIPs are known to show toxicity in vitro. This has made the use of SIPs
as potential drug delivery materials difficult. However, over the past several years, Gillies
has developed another polyacetal SIP, poly(ethyl glyoxylate) (PEtG), that holds the
potential to be non-toxic.46 Similar to PPHA, PEtG is a polyacetal SIP with a low Tc of
around -5 °C. The polymerization is carried out at -40 °C to -20 °C in the presence of a
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catalytic amount of triethylamine (TEA) (Scheme 8a). Our current hypothesis is that TEA
acts as a proton shuttle during the polymerization. The polymerization is believed to
initiate from trace amounts of hydrate present in the monomer solution. At room
temperature, non-end-capped PEtG chains spontaneously depolymerize back to ethyl
glyoxylate monomer units (Scheme 8b).

Scheme 8. (a) Synthesis of PEtG and (b) Depolymerization mechanism for PEtG and
subsequent hydration/hydrolysis of the corresponding small molecules.

The hemiacetal ends can be capped by the addition of chloroformate derivatives of
stimuli-responsive small molecules, creating carbonate linkages between the polymer and
end-cap. The most promising feature of PEtG is that in vitro these monomers ultimately
degrade into glyoxylic acid hydrate and ethanol, both of which should be relatively
nontoxic and can be processed by the human body.47 It is hypothesized that drug delivery
vehicles manufactured from PEtG could provide an SIP-based DDS in the form of
polymeric self-assemblies.
For PEtG to be a viable drug delivery material, the polymer needs to be stable in
biological conditions of 37 °C. To achieve this, the hydroxyl end groups of the polymer
are stabilized by reacting them with stabilizing small molecules. These molecules protect
the reactive ends of the polymer and hinder end-to-end depolymerization, resulting in a
polyacetal that is quite stable at physiological pH and temperature. A range of end-caps
have been reported for this purpose. The few that are important to this thesis are benzyl
chloroformate (BnCF), which is non-responsive and serves as a control (1.18); 6nitroveratryl chloroformate (NVOC-Cl), which is sensitive to UV light (1.19); and 2(pyridine-2-yl-disulfanyl)ethyl chloroformate (PDS-Cl), which is sensitive to reducing
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conditions (1.20) (Figure 9).48 These molecules react with hemiacetal alcohols at the
termini of the polymer to yield BnCO-, NVOC-, and disulfide-capped PEtG polymers. It
has been shown in previous work by Gillies and coworkers that these end-caps stabilize
the PEtG polymers and allow them to withstand temperatures over 120 °C without
degradation in the dry state.

1.18

1.19

1.20

Figure 9. Chloroformate-based molecules for end-capping PEtG.

From the past decade of research into SIPs as potential candidates for stimuli-responsive
DDSs, it is hypothesized that PEtG could be a promising material in this field due to its
amplified response to stimuli and its potentially non-toxic degradation products.

1.3 Polymeric Drug Delivery Systems
One important potential application of SIPs is in polymeric DDSs. Polymer assemblies
including micelles, worm-like micelles, vesicles, and solid-core particles have been
extensively researched and developed for biomedical and drug delivery purposes. PLA,
PGA, PCL, PEO and their copolymer assemblies have been extensively applied towards
drug delivery research with varying degrees of success.49-52 From decades of polymeric
self-assembly research, several important features for an efficient polymeric DDS have
been determined. First, the polymer must exhibit an acceptable host response and its
degradation products must be considered non-toxic.53 Second, there is a specific range of
sizes for a DDS to ensure it does not get cleared from the body before it can deliver its
payload.54 Third, the DDS must be capable of carrying significant loads of cargo and also
releasing their cargo in the short time frame they remain in circulation.55 DDSs that do
not meet at least these criteria, show inefficient treatment results in vivo.56
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1.3.1

Self-Assembled Nanostructures

Lipid-based vesicles were among the first nanotechnology DDSs.16 These structures
consist of a self-assembled sphere of phospholipids that surround a water droplet. It is
well understood that when phospholipids are placed in an aqueous environment, they
spontaneously arrange themselves in order to minimize unfavorable hydrophobichydrophilic interactions. This creates a bilayer where the hydrophobic tails of the
phospholipids are close to one another and oriented away from the aqueous surroundings.
This leaves the hydrophilic heads of the phospholipids arranged outward toward the
aqueous surrounds. Ultimately, spherical structures are formed with the inside filled with
the aqueous media (Figure 10a).

Figure 10. (a) Self-assembled phospholipid liposome and (b) Self-assembled polymersome.

Similar structures can be made using other biologically-based materials that possess
amphiphilic properties including polypeptides (Figure 10b) and polysaccharides.57 These
technologies have seen much clinical success due to their biocompatibility and low
toxicity in vivo.
Similar to amphiphilic phospholipids and polypeptides, polymers also exhibit selfassembling behavior in solution. Polymers with amphiphilic properties orient themselves
to minimize unfavorable interactions with the surrounding solvent. Amphiphilic polymers
are typically made by sequential polymerization of hydrophobic block and hydrophilic
blocks or by the conjugation of these blocks post-polymerization. Depending on the ratio
of the blocks, different self-assembled structures can be made.58 With a higher fraction of
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hydrophilic block, micelle structures are typically formed (Figure 11a). With a higher
fraction of hydrophobic block, vesicle structures are often formed (Figure 11c). Marginal
differences in the hydrophobic:hydrophilic ratio lead to intermediate structures like the
worm-like micelle (Figure 11b). For hydrophobic homopolymers, solid-core particles
form and can be suspended in aqueous solution by the addition of a surfactant to coat the
surface of the particles (Figure 11d).

Figure 11. Examples of self-assembled architectures based on polymers containing different
ratios of hydrophobic and hydrophilic blocks.

Biodegradable polymers can serve as alternatives to lipids. One benefit of using polymers
is their degradability can be tuned to control when and/or how fast a drug is released. The
common polyesters, PLA, PGA and their copolymers have been the most widely studied
for drug delivery.8, 13, 50 Degradation rates can be tuned in the range of weeks to years
using different compositions of these polymers. A major drawback is their relative
instability in blood compared to liposomal counterparts. Intravenous injection being one
of the most effective ways to treat disease, it is important to understand and develop
DDSs capable of withstanding the blood stream.59

1.3.2

Clearance of DDSs from the Body

When a therapeutic drug delivery vehicle is administered into a person’s blood stream, a
number of biological factors diminish or limit the overall efficacy of the DDS.53
Depending on how the DDS are administered into the body, they must bypass a number
of barriers in order to reach their therapeutic target. The body is effective at identifying
foreign objects within and has a variety of effective ways it can clear the system of these
foreign bodies. An intravenously administered DDS must make its way through a myriad
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of immune response cellular pathways and blood filtering organs before ultimately
making it to the targeted tissue.60 The barriers inherent to intravenous injection pose a
challenge for virtually all intravenously administered DDS. Specifically, the challenge of
how to effectively dose and get the physical drug to the tissue of concern before the host
removes them from the body.
One of the most important factors influencing a DDS’s ability to remain circulating in the
blood stream is its size.61,

62

Particles smaller than 20 nanometers in diameter will be

removed from circulation by the reticuloendothelial system (RES) and kidneys within a
few hours of injection. Particles with a diameter greater than 300 nanometers begin to
accumulate in the spleen and liver within minutes of injection.58 Therefore, to maximize
blood circulation time of a drug loaded DDS, the average size of the particles should be
around 100 nm. This size should be sufficiently large to avoid filtration by the kidneys
and slow the opsonization process of macrophages in the RES. It also should be small
enough to avoid being filtered by blood filtration organs like the spleen and liver.63
Based on these criteria, it is difficult to design a polymeric DDS that can effectively
shuttle a cargo to a target tissue before it is cleared from the body. First, the rate of
degradation needs to compete with the rate of clearance of the particles from
circulation.64 If the rate of degradation is too slow and a significant amount of drug
remains trapped inside the particles as they are cleared from the blood, incomplete
administration could occur. Blood circulation times of nanoparticles (NPs) are on the
order of hours; thus, degradation times need to be on the same timeframe. Second,
current stimuli-responsive DDSs rely on many stimulating events for complete release of
cargo. Stimuli-responsive polymers such as those discussed above require a high
concentration of stimulus due to the many stimulus-polymer interactions required for
degradation. In target tissues lacking a strong concentration of stimulus, these systems
may be inefficient at releasing cargo.65
The development of SIPs could potentially address these difficulties. Self-immolative
polymeric DDSs respond to low concentrations of specific stimuli leading to rapid release
of a payload in specific environments.48 This provides an amplified response to stimulus
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that is lacking in current polymer DDSs. The rapid depolymerization rates of SIPs also
negates the concern of clearance before the cargo is released.66

1.3.3

Efficiently Delivering Cargo

One of the most difficult problems regarding drug development is low solubility of
hydrophobic drugs in aqueous environments. It has been estimated that 40% of active
compounds identified through combinatorial screenings show poor water solubility67.
Poor solubility of hydrophobic drugs leads to complications including variable
bioavailability, slow onset of action and poor performance. This leads scientists to either
alter the design of the drug to increase its water solubility or to simply discard the
molecule all together. Polymeric DDSs aim to increase drug bioavailability and
effectiveness while also reducing drug toxicity by introducing a method to control
release.68 Polymer DDSs have proven to be an effective method to overcome the
difficulty of poorly soluble pharmaceutics. This is accomplished by either encapsulating
the drug within a hydrophobic polymer nanostructure or covalently binding the drug to a
water-soluble polymer via labile bonds that can be broken in vivo.69
NP-based DDSs in particular have emerged as effective methods for overcoming the
pharmacokinetic limitations of poor solubility and drug toxicity of medicaments. In these
DDSs, drugs can exist as a reservoir in the circulatory system with drug continually being
delivered to target tissue over time. Elongated circulation time led to the discovery of an
important characteristic of tumor cells, the enhanced permeability and retention effect
(EPR).70 The EPR is a phenomena observed when macromolecules, circulating in the
blood, demonstrate a heightened accumulation in tumors due to leaky vessels in these
tissues. This effect gives a passive targeting capability to NP DDSs for the delivery of
chemotherapeutics to tumors via the blood stream.

1.3.4

Emulsion Evaporation Technique for Nanoparticle
Synthesis

Several methods exist to produce NPs in the range of 10 – 300 nm. For hydrophobic
homopolymers, the general approach for the preparation of a DDSs is to encapsulate a
hydrophobic drug within a hydrophobic solid-core polymer particle that is dispersed in
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aqueous solution using surfactants.71 This approach often utilizes the oil-in-water (o/w)
emulsion-evaporation technique for the manufacturing of polymeric NPs (Figure 12).72

Figure 12. O/W emulsification for the encapsulation of a hydrophobic cargo within solid-core
polymeric NPs.

In an o/w emulsion, the hydrophobic polymer is first dissolved in an organic solvent.
Separately, an amphiphilic surfactant molecule is dissolved in the aqueous phase. The oil
phase is then added to the water phase and a form of mechanical energy such as stirring
or ultrasonication is introduced to produce the emulsion. After an emulsion is obtained,
the organic solvent is evaporated out of the nanodroplets leaving a suspension of polymer
coated with surfactant dispersed in the aqueous media.73
The surfactant’s purpose is to serve as a stabilizer between the hydrophobic polymer
particle with the surrounding aqueous environment. The surfactant allows for the oil
phase droplets to suspend in the aqueous environment upon formation. The organic phase
contains the polymer along with the hydrophobic cargo. The organic solvent is then
slowly removed by evaporation while stirring. After complete removal of the organic
phase, the particles remain suspended in the aqueous solution by a coating of surfactant.

1.4 Applications of SIPs in DDSs
In terms of drug delivery, polymeric NPs have been shown to improve drug targeting
capabilities, decreasing drug toxicity and increasing efficacy in a variety of different
hydrophobic therapies.74 These benefits are highly sought after for treatments of certain
diseases such as cancer with cytotoxic medicaments. Often, a chemotherapeutic is
administered systemically with the hope that the majority of chemotherapy will make its
way to infected tissue before it affects healthy tissue. It is unavoidable that some healthy
tissues will be affected in this method of administration leading to the unwanted sideeffects associated with chemotherapy treatments. Stimuli-responsive polymer NPs have

23

the potential to provide a way to not only target specific areas of the body, but to also
provide a “smart” characteristic to the drug. Upon encountering a certain stimulus related
to the target site, the “smart” system will release its cargo.69
To date, only a handful of SIP systems demonstrating potential for controlled release
have been reported. The first reported polymeric self-assembling system featuring a SIP
was by Dewit and Gillies in 2009.41 Their polycarbamate SIP, which was discussed in
section 1.2.4, was end-capped with poly(ethylene oxide) (PEO) through an ester linkage
providing an amphiphilic block copolymer. This copolymer was found to self-assemble
into NPs capable of encapsulating and subsequently releasing a fluorescent dye in
aqueous solution. This proof-of-concept application opened the door to other stimuliresponsive SIP delivery systems.
In 2010, Moore developed a microcapsule composed of a self-immolative poly(benzyl
carbamate) (PBC) similar to the polycarbamate reported by Shabat (Scheme 9). Pendant
protected alcohol moieties were conjugated to the aromatic rings. After polymerization of
the monomer, the polymer was end-capped with either a fluorenylmethyloxycarbonyl
(Fmoc) or tert-butyloxycarbonyl (Boc) group. The pendant alcohols were then
deprotected and converted to isocyanates. From here, microcapsules were synthesized via
an interfacial polymerization reaction between the isocyanates and 1,4-butanediol.75 To a
solution containing a surfactant was added the PBC. The PBC was dissolved in
etheylphenylacetate (EPA), which made up the core of the microcapsules. An emulsion
was formed between the two solvents and the resulting emulsion was heated at 70 °C for
1.5 h. Microcapsules in the 5 – 40 µm size range were produced using this method
(Figure 13).
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Figure 13. PBC-based core-shell microcapsules. (Reprinted with permission from Moore et. al.,
2010. Copyright 2017 American Chemical Society.)

Scheme 9. A PBC with pendant tert-butyldimethylsilyl-protected alcohols.

Upon Boc or Fmoc removal by the addition of HCl or piperidine respectively, the
capsules were degraded. To measure the degradation, the amount of EPA released was
monitored by gas chromatography. Under these conditions, it was found that close to
100% of the contents were released within 48 h whereas controls showed less than 10%
release.
The Phillip group developed and used PPHA to manufacture microcapsules capable of
carrying a hydrophilic cargo dissolved in an aqueous environment.45 An improvement to
the Moore’s method was the use of flow-focusing microfluidics which gives control over
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the thickness of the microcapsule shell. A microfluidics device used a pump to push a
water-soluble cargo dissolved in an aqueous, surfactant-containing solution through an
organic, polymer-containing solvent well. With control of the flow rate, droplets of
aqueous phase are coated with polymer-containing organic phase. These particles then
passed through the organic phase into a separate aqueous phase. The microcapsules can
then be collected and remaining organic solvent evaporated from the shell. PPHA
microcapsules were made with responsiveness to fluoride by capping the PPHA terminus
with a silyl ether moiety with similar cargo release rates observed.
More recently, Liu reported amphiphilic block copolymers that incorporated a
hydrophobic, polycarbamate SIP block conjugated to a hydrophilic poly(dimethyl
acrylamide) (PDMA) block (Scheme 10, Figure 14).76 Using self-assembly techniques,
self-immolative polymersomes (SIPsomes) around 250 nm in diameter were
manufactured with the capability of encapsulating both hydrophilic and hydrophobic
cargos. Hydrophilic cargos were dissolved in the aqueous core while hydrophobic cargos
were encapsulated in the hydrophobic polymer shell. Several stimuli-responsive end-caps
were used to manufacture SIPsomes capable of triggerable degradation to visible light,
UV light, and reduction (Scheme 10).

Figure 14. PBC-PDMA multi-block copolymer SIPsomes and their triggerable cargo release.
(Adapted with permission from Liu et. al., 2014. Copyright 2017 American Chemical Society.)
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Scheme 10. (a) visible light, (b) UV light, and (c) reduction-sensitive PBCs.
To take advantage of the dual loading potential of this system for combinational therapy,
a co-encapsulation of hydrophobic camptothecin (CPT) and hydrophilic doxorubicin
(DOX) was done. For end-capped polymers responsive to reduction, controls showed
only ~4% DOX and ~19% CPT released over 20 h. Upon the addition of 31 mmol
glutathione (GSH), a biological reducing agent, ~86% DOX and ~82% CPT were
released over the same timeframe.
Gillies and coworkers recently showed the promising application of PEtG as a drug
delivery vehicle.48 The promising advantage of PEtG is that the degradation products
(i.e., ethanol and glyoxylic acid) have the potential to exhibit low toxicity. PEtG was endcapped with modified linker end-caps capable of conjugating to PEO to form amphiphilic
block copolymers. These modified end-caps were still capable of undergoing their
respective stimuli-responsive reactions, resulting in triggered degradation of the SIP
blocks. These block copolymers were self-assembled to form micellular NPs capable of
encapsulating hydrophobic cargos (Figure 15).

Figure 15. Stimuli-responsive NPs based on a triblock SIP. (Reprinted with permission from
Gillies et. al., 2017. Copyright 2017 American Chemical Society.)
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These particles showed triggerable degradation in response to thiol reducing agents, UV
light, H2O2 and combinations of these depending on the linker end-caps used. Nile red,
DOX, and curcumin were all loaded into the particle cores. Their release in response to
stimulus was measured. The disulfide-capped PEtG showed appreciable payload release
in concentrations of stimulus, such as dithiothreitol (DTT), as low as 0.1 mM over 48 h
and close to complete release at higher concentrations of the stimulus (10 mM) over the
same timeframe. Similar studies were conducted using various responsive end-caps
concluding triggerable release of cargo with different stimulants simply by altering the
PEtG end-cap.

1.5 Thesis Objectives
The objective of this work was to prepare and study surfactant-coated PEtG solid-core
particles for drug delivery. In contrast to the NP systems described above, this does not
require the preparation of block copolymers. The first goal was to optimize conditions for
generating PEtG NPs. In particular, we targeted a reproducible method providing a mean
particle diameter (Z-avg.) of ~100 nm for the reasons described above. The size and
morphology was characterized by dynamic light scattering (DLS) and transmission
electron microscopy (TEM).
Additionally, PEtG was blended with varying ratios of PLA. As discussed above, PLA is
a well-known and established biocompatible and biodegradable polymer. It was
hypothesized that the addition of this polymer to create PLA-PEtG blends would increase
the hydrophobicity and rigidity of the NP cores allowing for tunable rates of release to
this DDSs based on wt% PLA. Each PLA-PEtG blend was characterized by
thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) in order
to determine the phase separation behavior of these polymers.
After determination of the synthetic route and characterization of these particles, the
focus shifted toward testing the stimuli-responses behavior of these solid-core PLA-PEtG
particles. A fluorescent small molecule was used as a molecular probe to test for
triggerable release of a hydrophobic cargo. Furthermore, a model drug was encapsulated
and the release kinetics studied. Investigation into the optimal loading efficiency and
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percent weight cargo was determined for drug-loaded PLA-PEtG NPs. Triggerable
release was tested using a UV-responsive end-cap. This end-cap serves as an ideal model
system as it can be cleanly and rapidly removed by irradiation with UV light. However,
in most applications, it would not be possible to apply UV light in vivo. Therefore, to
further investigate the possibility of triggering release using biologically accessible
triggers, an end-cap responsive to reducing agents was also investigated as a potential
triggerable end-cap.
Finally, the triggerable release of drug-loaded PLA-PEtG NPs was tested in vivo in
MDA-MB-231

cells.

3-(4,5-dimtheylthiazol-2-yl)-2,5-diphenyltetrazolium

bromide

(MTT) assays will be conducted to test for viability of this cell line treated with drugloaded PLA-PEtG particles.
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2

Experimental

2.1 General Procedures and Materials
6-Nitroveratryl carbonate end-capped poly(ethyl glyoxylate) (NVOC-PEtG) (Mn =
70,000 g/mol, Ð = 2.4), benzyl carbonate end-capped poly(ethyl glyoxylate) (BnCOPEtG) (Mn = 56,000 g/mol, Ð = 1.6), 2-(pyridine-2-yl-disulfanyl)ethyl carbonate endcapped poly(ethyl glyoxylate) (disulfide-PEtG) (Mn = 24,000 g/mol, Ð = 1.4) were
prepared as previously reported.46 All other chemicals were obtained from commercial
suppliers and used without further purification. TGA was performed on a Q50 from TA
Instruments with the following conditions: heat rate of 10 °C/min ranging from 35−500
°C under nitrogen atmosphere. Size-exclusion chromatography (SEC) was performed in
THF at 1 mL/min using a viscotek GPC Max VE2001 solvent module equipped with a
Viscotek VE3580 RI detector operating at 30 °C, two Agilent Polypore (300x7.5mm)
columns, and a Polypore guard column (50x7.5mm). A calibration curve was obtained
using polystyrene standards. Fluorescence spectra were obtained using a QM-4 SE
spectrometer from Photon Technology International equipped with double excitation and
emission monochromators. UV-visible spectra were obtained on a Varian UV/Vis Cary
300 spectrophotometer. Centrifugation was performed using a Clinical 200 VWR
centrifuge at 6000 rpm. Ultrapure water was obtained from a Barnstead EASYpure II
system. Sonication was conducted using a Branson 450 digital sonifier. Spectra/Por
regenerated cellulose membranes were used for dialysis. 0.22 µm Acrodisc Syringe Filter
Non-Pyrogenic 13 mm were used to filter all particle suspensions.

2.2 Preparation of Poly(ethyl glyoxylate)-poly(D,L-lactic
acid) Blends
Poly(ethyl glyoxylate)-poly(D,L-lactic acid) (PLA-PEtG) blends were made by
combining 9.0, 7.0 and 5.0 mg PEtG with 1.0, 3.0 and 5.0 mg, respectively, of PLA to
obtain blends that were 10, 30 and 50 wt% PLA. These polymer samples were then
dissolved in dichloromethane (1 mL) and stirred for 30 min to allow for complete mixing
of the polymers.77 The solvent was removed in vacuo for analyses.
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2.3 Method for Preparing Nanometer-sized Particles
PEtG (10.0 mg) was dissolved in dichloromethane (1 mL). A separate solution of sodium
cholate (50 mg) was prepared in distilled water (10 mL) for a final concentration of 12
mM. The organic phase was added to the aqueous phase by glass pipette into a 20 mL
glass vial. The sonication amplitude was set to 10% on a Branson 450 digital sonifier.
The biphasic mixture was then sonicated for three 30 s intervals with 10 s breaks in
between for a total of 90 s of sonication over 120 s.78 To the resulting emulsion mixture,
a magnetic stir bar was added and the solution was vigorously stirred overnight (16 h) to
evaporate the organic phase. After evaporation of the organic phase, the particle
suspension was dialyzed (3,500 g/mol molecular-weight cut-off (MWCO) dialysis
membrane, 8 h) against distilled water to remove any excess sodium cholate. The particle
suspension was then passed through a 0.22 μm syringe filter.
To create PLA-PEtG blended NPs, select weight percentages of PLA were incorporated
into the PEtG organic phase. Specifically, 10 wt%, 30 wt% and 50 wt% PLA-PEtG
blends were prepared as described above. The dichloromethane solutions of these blends
were added to the aqueous phase, then the biphasic mixture was sonicated, dried and
dialyzed and the resulting particles were dialyzed by the methods described above.

2.4 Dynamic Light Scattering
DLS was performed using a Zetasizer Nano ZS instrument from Malvern Instruments at
25 °C at a concentration of 0.1 mg/mL of polymer assemblies. The Z-average diameter
and polydispersity index for each series of particles was measured in triplicate.

2.5 Preparing Particles for Imaging
TEM imaging was done using a Phillips CM10 microscope operating at an acceleration
voltage of 80 kV with a 40 µm aperture. 20 µL of particle suspension (1.0 mg/mL) was
placed on a copper grid. The resulting sample was air-dried for 24 h before imaging.
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2.6 NP Degradation Studied by DLS
NPs were prepared as above, with the exception that the suspensions were dialyzed
against 100 mM, pH 7.4 phosphate buffer (1 L, 24 h, water changed once at ~12 h). The
polymer concentration was 0.1 mg/mL. The count rate was measured by DLS while
fixing the attenuator at 7. For NVOC-PEtG and BnCO-PEtG, irradiation with UV light
was performed in an ACE Glass photochemistry cabinet containing a mercury light
source (450 W bulb, 2.8 mW/cm2 of UVA radiation) for 30 minutes. For disulfide-PEtG
and the BnCO-PEtG control, DTT (7.7 mmol) was added. Control experiments without
stimulus were also included in each case after applying the stimulus, the samples were
incubated at 37 °C in the dark and the DLS count rate was measured at selected time
points. Each experiment was performed and studied in triplicate.

2.7 Loading and Release of Nile Red
Nile red-loaded NPs were prepared by the addition of Nile red (0.1 mg, 0.03 mmol) to the
organic phase containing defined weight percentages of PEtG and PLA. The organic
phase was allowed to stir for several hours to facilitate complete mixture of the blends
and Nile red. The polymer-Nile red solution was added to the surfactant-containing
aqueous phase and subjected to sonication, as described above. After sonication and
evaporation, the particle suspensions were dialyzed against water using a 3,500 g/mol
MWCO dialysis membrane for 24 h to remove excess surfactant and any trace
unencapsulated Nile red.
To test for triggerable release of Nile red from the particles, NPs were again prepared as
above with 0.1 mg Nile red added to the organic phase. The particle suspensions were
dialyzed against 100 mM, pH 7.4 phosphate buffer. After 24 h of dialysis, the solutions
were diluted 10-fold in pH 7.4 phosphate buffer to yield a Nile red concentration (3 µM)
within the detectable range of the fluorimeter. Using an excitation wavelength of 540 nm,
the initial emission intensity of Nile red was measured at 602 nm to obtain fluorescence
at T0 (starting time). At this point, the appropriate stimulus (UV light for NVOC-PEtG
and DTT for disulfide-PEtG) was added, or not added in the case of controls, and the
solutions were placed in a 37 °C oven. Fluorescence measurements were taken at
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incremental time points over a 24 h period. By comparing the fluorescence at each time
point with its initial fluorescence, the percent initial fluorescence was calculated. These
measurements were taken in triplicate and conducted for each of the three polymer
blends.

2.8 Preparation of Letrozole-Loaded NPs
NPs were prepared as above with the addition of letrozole (30 wt%, 3 mg, 0.86 mmol)
dissolved in the organic phase with the polymer mixtures before sonication. After
sonication, the suspensions were again dialyzed in a 3,500 g/mol MWCO membrane for
24 h to remove any unencapsulated letrozole. After dialysis, the solutions were passed
through a 0.22 μm syringe filter and a portion was lyophilized to calculate the loading
efficiency and drug wt%. The lyophilized pellet was weighed and then dissolved in 1 mL
of acetonitrile. The absorbance of the resulting solution was measured by UV-visible
spectroscopy at 240 nm. The concentration was calculated based on a letrozole
calibration curve (ɛ = 30,600 L/mol·cm, acetonitrile) and the loading efficiency and drug
content of the NPs was calculated as followed:
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =

𝐷𝑟𝑢𝑔 𝑤𝑡% =

𝐷𝑟𝑢𝑔 𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑
× 100
𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑒𝑑

𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝐷𝑟𝑢𝑔 𝑀𝑎𝑠𝑠
× 100
𝑇𝑜𝑡𝑎𝑙 𝑀𝑎𝑠𝑠

2.9 Triggerable Release of Letrozole
For drug release studies, NPs were prepared as described above with the exception that
after sonication and evaporation, the particle suspensions were dialyzed against 100 mM,
pH 7.4 phosphate buffer (1 L, 16 h, dialysate exchanged at ~8 h) using a 3,500 g/mol
MWCO membrane to remove any unencapsulated letrozole and excess surfactant. The
particles were then filtered through a 0.22 µm syringe filter and diluted 10-fold with 100
mM, pH 7.4 phosphate buffer. An initial absorbance measurement was taken (T0).
Subsequently, the appropriate stimulus was introduced as described above for the DLS
experiments. The samples were then each placed in an individual 3,500 g/mol MWCO
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dialysis membrane and dialyzed in 7.4 phosphate buffer in a 37 °C oven. To measure the
letrozole release rates, 200 µL of each sample were taken at incremental time points and
passed through a 0.22 µL syringe filter. From the filtered solution, three 50 µL aliquots
were taken and diluted into 1 mL of acetonitrile to fully dissolve the polymer particles
and remaining encapsulated drug. The absorbance was measured at 240 nm (ɛ = 30,600
L/mol·cm). Release rates were obtained by plotting the absorbance at each time point as a
percentage of initial absorbance.

2.10 Triggerable Release of Celecoxib
For celecoxib release studies, disulfide-PLA-PEtG and BnCO-PEtG NPs were prepared
as described above and dialyzed against 100 mM, pH 7.4 phosphate buffer (1 L, 16 h,
dialysate exchanged at ~8 h) using a 3,500 g/mol MWCO membrane to remove any
unencapsulated celecoxib and any excess surfactant. They were then filtered through a
0.22 µm syringe filter and diluted 10-fold with 100 mM, pH 7.4 phosphate buffer. An
initial absorbance measurement was taken by removing 200 µL of each sample and
dissolving it in 1 mL acetonitrile. The absorbance was measured at 253 nm (ɛ = 16,400
L/mol·cm for celecoxib based on a calibration curve in the same medium) in order to
quantify the total amount of drug initially encapsulated in the system. Subsequently, the
appropriate stimulus was introduced as described above for the reduction-responsive DLS
experiments. The samples were then each placed in an individual 20 mL vial with a small
bar magnet, stirred at low rpm and kept in a 37 °C oven for the duration of the study. At
distinct time points, each sample was centrifuged for three minutes at 6,000 rpm to
separate the precipitated drug from the particles and encapsulated drug that remained
suspended in the medium. The suspension was decanted back into the initial vial and
placed back into the oven while the pellet was dissolved in 1 mL acetonitrile and the
absorbance at 253 nm was taken to quantify the amount of drug that had been released
and consequently precipitated. This amount was compared to the initial amount of
encapsulated drug in order to determine the percentage of released drug.
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2.11 Cell Toxicity Study
Dulbecco’s modified Eagle medium (DMEM) with 4.5 g/L

D-glucose

and 110 mg/L

sodium pyruvate was obtained from Gibco. Penstrep, 10% fetal bovine serum (FBS) and
trypsin-EDTA (0.25%) were obtained from Gibco. The MDA-MB-231 cells were
cultured in DMEM with 10% FBS and 100 units/mL of Penstrep in an atmosphere of 5%
CO2 at 37 °C. The cells were seeded in a 96 well plate (Corning Flat Bottom Plate) at a
concentration of 5,000 cells/well. Cells were placed in an incubator for 24 h (37 °C, 5%
CO2). Following the incubation, the medium was aspirated and replaced with various
treatments of NPs of 1, 0.5, 0.25, 0.13, 0.06 mg/mL. For UV-sensitive particle studies,
the cells were irradiated with 30 minutes of 360 nm light using light emitting diode
flashlights. Negative controls include either just media or the test material. The cells were
then incubated at 37 oC for 48 h. The medium was then aspirated and replaced with 100
µL of

fresh

medium

containing

0.5

mg/ml

(3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide) (MTT) reagent and allowed to react for 4 h in the incubator
at 37 °C. After 4 h the plate was removed and the MTT reagent solution was aspirated. 50
µL of dimethyl sulfoxide was added to each well to solubilize the metabolic reagent of
MTT. The plate was then placed in a plate reader (Tecan Infinite M1000 Pro, absorbance
540 nm) to obtain cell counts. No biological replicates were performed; six technical
replicates were performed per treatment.

35

3

Results & Discussion

3.1 Stimuli-Responsive Poly(ethyl glyoxylate) Synthesis
PEtG was synthesized as previously reported (Scheme 11).46 The purity of ethyl
glyoxylate monomer was the limiting factor on the molecular weight of PEtG. The
monomer was purchased as a 50:50 volume ratio in toluene. After two distillations over
phosphorus pentoxide (P2O5) as a drying agent, pure monomer was obtained. The
monomer was cooled to −20 °C and polymerization initiated by adding a catalytic
amount of TEA. The mechanism of polymerization is hypothesized to be initiated from
trace amounts of hydrated monomer. After polymerization, the polymer was held at −20
°C and the desired chloroformate-functionalized end-cap was added. In this work,
polymers with three different stimuli-responsive end-caps were prepared: NVOC-PEtG,
which is responsive to UV light; disulfide-PEtG, which is responsive to reducing agents
such as DTT; BnCO-PEtG, which is non-responsive and serves as a control. The molar
mass data for the polymers used in this work is shown in Table 1.

Table 1. Average molecular weight (Mn) and polydispersity of end-capped PEtG used.

polymer

Mn (SEC) (g/mol)

Ð

To (°C)

NVOC-PEtG

70,000

2.4

203

disulfide-PEtG

24,000

1.4

191

BnCO-PEtG

56,000

1.6

162

36

Scheme 11. Synthesis of different classes of PEtGs.

3.2 Emulsion Optimization
3.2.1

Determination of Optimal Surfactant Concentration

One of the most common surfactants used in NP research has been PVA due to its
biocompatibility and non-toxicity.61 However, previous work done by the Gillies group
determined that PVA used as the surfactant for PEtG emulsion methods gave particles
diameters of 400 nm - too large to be optimal for intravenous drug delivery.74 Further
research on appropriate surfactants concluded that PEtG NPs stabilized with sodium
cholate as the surfactant could be manufactured with particle sizes of 120 nm.79 Cholic
acid (3α,7α-trihydroxy-5β-cholan-24-oic acid) is a primary bile acid produced by the
liver. The sodium or potassium salts of cholic acid are water dispersible and are naturally
used by the body in its digestion of fats and oils. Therefore, sodium cholate can act as a
biocompatible surfactant for NPs.80
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Parameters of the O/W emulsion technique were investigated with efforts focused on
preparing particles with diameters in the 100 nm range.81 The two variables found to
contribute the most towards controlling the diameter were surfactant:polymer ratio and
sonication time. As the particles get smaller, their surface area increases which increases
the overall oil-water interactions. Therefore, to get smaller particles, higher
concentrations

of

surfactant

were

required.

To

determine

the

appropriate

surfactant:polymer ratio, the concentration of PEtG was kept constant (1 mg/mL) while
varying the surfactant concentration from 0 mg/mL to 100 mg/mL. The biphasic mixture
was subjected to two minutes of sonication and the resulting emulsion was dried and then
dialyzed in distilled water as described above. The particle diameter was then measured
by DLS. As expected, 0 mg surfactant led to precipitation of polymer after evaporation.
As the surfactant concentration increased, the diameter of the particles decreased (Figure
16).
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Figure 16. Concentration of sodium cholate vs. Z-avg. while the concentration of PEtG was kept
constant at 1 mg/mL.

Although a meaningful change in the Z-avg. was not detected by measuring the diameter
of these systems, at low concentrations of surfactant, significant precipitation of polymer
was observed. This can be attributed to the necessity of a high concentration of surfactant
for small particles due to the high surface area. A sodium cholate concentration of 12 mM
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was found to yield the desired particle diameter with no appreciable precipitation of
polymer. This gave a surfactant:polymer weight ratio of 5:1.

3.2.2

Determination of Optimal Sonication Time

The second major factor in controlling the particle diameter was the sonication time. To
examine the effect of the sonication, the relationship between sonication time to particle
diameter was studied. The PEtG concentration was fixed at 1 mg/mL as above, and the
sodium cholate concentration was fixed at 5 mg/mL. The two solutions were combined
and emulsified using sonication for varying lengths of time. The resulting emulsion was
then stirred overnight and purified by dialysis as above. The resulting particles were
measured using DLS to determine the Z-avg. It is known that prolonged shearing forces
introduced by sonication can cleave polymer backbones over time. With the relatively
labile polyacetal backbone of PEtG, it was important to find the minimum amount of
sonication time needed to produce NPs close to 100 nm (Figure 17).82 The data showed
significant decrease in particle size up to approximately 90 s. After that, the particle size
appeared to not change significantly with increased sonication time. With this data, along
with results presented in Figure 16, all particle batches going forward were performed
under Table 2 conditions.
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Figure 17. Emulsion sonication time vs. Z-avg. for PEtG NPs while keeping the concentration of
PEtG constant at 1 mg/mL and sodium cholate concentration at 5 mg/mL.
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Table 2. Emulsification conditions for the production of 100 - 150 nm-sized PEtG-based NPs.
Sodium Cholate
(mg)

PEtG
(mg)

D.I. H2O
(mL)

CH2Cl2
(mL)

Sonication Time
3 rounds (30 s) with

50

10

10

1
intervals (10 s)

3.2.3

PLA-PEtG Polymer Blend Characterizations

PEtG was anticipated to provide rapid release upon stimulation. To provide further
control and tuning of the release properties, PEtG was blended with varying weight
percentages of PLA. It was anticipated that the PEtG phases of NPs would provide a
burst release at the target, while the polyester domains would afford continual slow
release as these domains would degrade more slowly. The presence of a non-stimuliresponsive polymer would lead to increase in overall degradation time which may lead to
tunability of cargo release. Specific weight percentages of PLA were substituted for
PEtG. Blends of 0 wt%, 10 wt%, 30 wt%, 50 wt%, and 100 wt% PLA were prepared by
dissolving the two polymers in dichloromethane.
Characterization of each polymer blend was conducted using both thermogravimetric
analysis (TGA) and differential scanning calorimetry (DSC). TGA data showed two-step
thermal degradation in the three blends and the blend ratios were consistent with the
incremental weight percentages of PLA present in each sample (Figure 18). Pure PLA
matched literature values of degradation temperatures showing PLA stable up to 300
°C.83 The PEtG sample matched reported values of 180−200 °C for end-capped PEtG.46
The addition of PLA appears to stabilize PEtG in some way. This can be seen by the
increase in onset degradation temperature (To) of PEtG in each of the three blends. The
degradation of PEtG increased about 100 °C by the incorporation of 10 wt% and 30 wt%
PLA, and even more so with 50 wt% PLA. This could be due to favorable intermolecular
forces between regions of the two polymers.
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Figure 18. TGA data for the PLA-PEtG blends.

DSC data showed the two polymers were mostly phase separated in the blends (Figure
19). This can be seen from the two distinct glass transition temperature (Tg) values
arising from the two different polymers (Table 3). The Tg for PEtG can be clearly seen for
each blend and matches the literature value of about −5 °C. There may be some slight
miscibility between these two polymers because the reported Tg for PLA is 50 °C, but the
Tg values for PLA in the blends range from 41 to 46 °C. In addition, the Tg of PEtG
increased from −8 °C for the pure PEtG to −1 °C for the 50% PLA blend.
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Figure 19. DSC thermograms recorded for pure PEtG, pure PLA and the three blends.

Table 3. Tgs recorded for the PLA-PEtG blends.

Blend

PEtG Tg (°C)

PLA Tg (°C)

100% PEtG

−7.6

-

10% PLA

−5.3

43.6

30% PLA

−3.2

40.8

50% PLA

−1.1

39.8

100% PLA

-

46.0

The immiscibility of these polymers suggests microphase separation of the polymers.
When PEtG is degraded, a porous PLA scaffold should be left which will rely on random
hydrolysis to degrade completely. The phase separation suggests an initial burst release
of cargo followed by a slower release of residual cargo encapsulated within the remaining
PLA scaffold. The burst release would then be incrementally less with increasing PLA
content, while the fraction undergoing slow release should increase. With a better
understanding of the nature of these polymer blends in hand, the synthesis of these
particles with their varying blends was investigated and their properties analyzed.
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3.3 Characterization of Particles
3.3.1

Characterization of Particles by DLS

The first method of characterization performed was the determination of the Z-avg. The
diameter for each blended batch of particles was determined using DLS. Each particle
suspension was prepared using conditions described earlier (section 3.2.2). Subsequently,
the particle suspensions were diluted to 0.1 mg/mL with distilled water to give
appropriate concentrations for DLS. In Figure 20 data are presented for the five blend
compositions. The Z-avg. diameters ranged from 128–144 nm and did not change
significantly with the incorporation of PLA. The PDI values ranged from 0.03–0.26,
which is considered relatively low. A summary of these DLS diameter distributions is
shown in Table 4.

Figure 20. Representative DLS diameter distributions of the PLA-PEtG blends: (a) intensity
distributions and (b) volume distributions.

43

Table 4. Z-avg. and polydispersity indices for the PLA-PEtG blends.

Blend

3.3.2

Z-avg. (nm)

PDI

0% PLA

144 ± 13

0.19 ± 0.07

10% PLA

137 ± 19

0.26 ± 0.11

30% PLA

128 ± 7

0.11 ± 0.03

50% PLA

133 ± 8

0.12 ± 0.03

100% PLA

132 ± 10

0.13 ± 0.04

Characterization of Particles Using Transmission
Electron Microscopy

With understanding of the blend characteristics and particle diameters in hand, it was
important to image the particles to confirm the morphologies and the particle diameters.
Due to the inability to freeze dry low PLA-content particles because of the low Tg of
PEtG, scanning electron microscopy (SEM) proved difficult as the particles tended to
fuse together. Therefore, TEM was employed as the imaging technique for the particles.
Using this imaging technique, samples prepared from particle suspensions could be
made, bypassing the need to freeze dry.
Figure 21 shows images for pure PEtG particles and those prepared from each of the
three blends. The particle diameters observed by TEM were in general smaller than those
measured by DLS. The observation of smaller diameters in TEM imaging is quite
common, as TEM measures the samples in their dehydrated state whereas DLS measures
the samples in their hydrated state. In agreement with the DLS results, increasing the
PLA content to 30 wt% (Figure 21c) and 50 wt% (Figure 21d) does not seem to
destabilize the morphology of the particles even though the two polymers are immiscible.
The particles in these samples appear to be spherical and monodisperse.
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Figure 21. Transmission electron micrographs of NPs prepared from (a) 100% PEtG, (b) 10 wt%
PLA, (c) 30 wt% PLA, (d) 50 wt% PLA.

3.4 Triggerable Degradation Studies
3.4.1

Degradation Measured by DLS

After it was concluded that PEtG could be successfully blended with PLA and made into
relatively monodisperse NPs, investigating the triggerable degradation nature of these
particles was the next step. In addition to NVOC-PEtG which was used for the above
work, particles were prepared from disulfide-PEtG and BnCO-PEtG by the same method
described above. Changing only the end-cap did not lead to any significant changes in the
particle diameter or morphology as determined by DLS and TEM (Figures A-3 – A-5 in
the appendix).
DLS was employed to test for degradation of particles in response to stimuli. This
technique can be used to probe for particle degradation because the count rate is
proportional to both the number of particles in suspension as well as their size. A
decrease in either the size or number of particles arising from degradation would lead to a
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reduction in the count rate. The appropriate concentration for the DLS studies of the
particle suspensions was found to be 0.1 mg/mL. Keeping the attenuator fixed, the light
scattering count rate was measured initially and then at various time points after
introduction of the stimulus. Control experiments involved application of the stimulus to
non-responsive BnCO-PEtG particles to account for any non-specific effects on the
particles. Each ratio of PEtG:PLA was studied.
Figure 22 shows the response of the NVOC-PEtG and BnCO-PEtG (PEtG-control)
particles to 30 minutes of UV irradiation. Two important observations came from this
study. First, for each PEtG:PLA ratio of NVOC-PEtG particles there is a rapid decrease
in count rate over the first hour following UV irradiation that likely corresponded to
degradation of particles. On the other hand, the scattered light intensity from the BnCOPEtG control particles stayed relatively constant at 100% of their initial count rate over a
24 h period. Secondly, with increasing PLA content in the particles, there was a plateau
of the degradation which corresponded approximately to the amount of PLA in the
particles. Pure PEtG particles appeared to approach zero counts at the 24 h time point, 10
wt% particles degraded to roughly 10% of their original count rate and then remained
constant, 30 wt% plateaued at 30% of the initial count rate and 50 wt% PLA particles
plateaued at 50% of the initial count rate. Also, light scattered from the pure PLA
particles remained constant at 100% original counts over the 24 h period.
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Figure 22. % Initial scattering count rate (DLS) vs. time for NVOC-PEtG and BnCO-PEtG
control particles following UV irradiation for 30 min.

To demonstrate the system can show responsiveness to several different stimuli just by
changing the end-cap, the study was repeated for disulfide-PEtG, which contains an endcap susceptible to reduction through its disulfide linkage. The reducing agent used to
trigger the end-cap was DTT. Figure 23 shows the DLS count rate over a period of 48 h
following the addition of 7.7 mmol DTT to the particles. It was observed that overall, the
reduction in count rate occurred more slowly than for the NVOC-PEtG particles in the
UV study. There are two factors that may be causing this: 1) the UV reaction could
proceed at a faster rate than the reduction reaction; 2) the DTT is limited by only being
able to react with surface end-cap groups first allowing fewer reactions to occur
simultaneously whereas UV light can penetrate past the surface. Again, the particles
containing less PLA underwent larger reductions in the count rate over the experiment,
likely corresponding to more complete degradation. The scattered light intensities from
the PEtG-control and pure PLA particles all remained near 100% of their original values.
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Figure 23. % Initial scattering count rate (DLS) vs. time for disulfide-PEtG and BnCO-PEtG
control particles following the addition of 7.7 mmol DTT.

Overall, the data collected for both NVOC-PEtG and disulfide-PEtG show that it is
possible to trigger degradation of the particles specifically by matching the stimulus with
the end-cap and that it appears possible to trigger different percentages of degradation by
tuning the PLA content in the particles.

3.4.2

Triggerable Release of a Fluorescent Probe

As an initial study to test for triggerable release of an encapsulated cargo, a fluorescent
cargo molecule was used as a probe. The same conditions were used as for the DLS study
where NVOC-PEtG particles were used as the UV-light responsive particles and
disulfide-PEtG were used as reduction responsive particles. BnCO-PEtG particles were
again used as a non-stimuli responsive control. Nile red dye was selected as an
appropriate proof-of-concept cargo. Nile red can be loaded at low concentrations which
allows for effective probing of triggerable release of cargo by measuring fluorescence of
particle suspensions at incremental time points post-stimulus exposure. In hydrophobic
environments, Nile red is highly fluorescent, while, in hydrophilic environments, Nile red
undergoes aggregation and its fluorescence is significantly quenched.84 Therefore, Nile
red encapsulated within PEtG NPs will fluoresce and as it is released into the surrounding
aqueous environment, the fluorescence will decrease.
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Nile red encapsulated NPs were prepared by the same method described above except
that 2 wt% of Nile red relative to polymer was incorporated into the dichloromethane
phase to load the particles. Batches were made for each of the PLA weight percentages as
above, including pure PEtG and pure PLA. Qualitatively, the fluorescence of Nile red in
different hydrophobic environments can be seen in Figure 24. The far-right vial (24e)
contains the 100% PLA Nile red-loaded particles. This represents the most hydrophobic
environment for the Nile red and this is seen by the intensity of the color.85 Moving to the
left are NVOC-PEtG samples with decreasing wt% PLA. With decreasing wt% PLA in
the particles, the intensity of the color drops off with each incremental decrease of PLA.
This further supports the different environments present in the cores of the different PLAPEtG blended particles. The PLA adds hydrophobic character to the particles, whereas
the PEtG is more hydrophilic which could help facilitate more Nile red encapsulation in
the particles with the higher PLA content, leading to a more intense color.

Figure 24. Nile red-loaded PLA-PEtG NP suspensions: (a) 100% PEtG, (b) 10 wt% PLA, (c) 30
wt% PLA, (d) 50 wt% PLA, and (e) 100% PLA.

The initial fluorescence intensity was measured for each sample along with controls.
During the duration of the study, the samples were kept in a 37 °C oven in 100 mM, pH
7.4 phosphate buffer. Each successive time point following application of the stimulus
was measured as a percent of initial fluorescence. An example of these data taken for 0%
PLA NVOC-PEtG is shown in Figure 25. The graph tracks the fluorescence from T0,
which was taken for NVOC-PEtG particles prepared with 100% PEtG before UV-light
exposure up to 60 minutes after exposure. The data can further be processed to plot a
percent initial fluorescence over time by taking the maximum value for each time point as
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a percentage of the initial fluorescence (Figure 26). Using these data allows for
comparison between the different weight percentage PLA-PEtG particles and their Nile
red release rates.

Figure 25. Fluorescence emission spectra of Nile red-loaded 100% NVOC-PEtG NPs over a
period of 1 h post-UV exposure.
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Figure 26. Fluorescence behavior of Nile red-loaded 100% NVOC-PEtG NPs.

The Nile red fluorescence experiments were conducted for both UV light-responsive and
reduction-responsive particles using NVOC-PEtG and disulfide-PEtG, along with BnCOPEtG control NPs for each stimulus. The fluorescence changes over time following
application of the stimulus for the different PEtG:PLA ratios are shown in Figure 27 for
UV light and Figure 28 for DTT as a stimulus. The findings correspond with previous

50

experimental results from the DLS degradation studies. Specifically, these data show that
the NVOC-PEtG particles exhibited a significant burst release of Nile red within the first
hour after being exposed to UV light. This is due to the PEtG fraction of the particles
being degraded. Each different PLA wt% then plateaued at a different value,
corresponding to the remaining PLA in the particles. In other words, a percentage of the
particle’s hydrophobic core remained, which was still able to encapsulate Nile red within
a hydrophobic environment. Figure 28 shows that the release of Nile red following
application of DTT to the disulfide-PEtG NPs was slower than for the light-responsive
particles. As for the DLS study, this can likely be attributed to slower end-cap cleavage.
As for the NVOC-PEtG particles, increasing the PLA content resulted in a higher
retention of Nile red. In each experiment, the controls of BnCO-PEtG particles with
applied stimuli showed a 10 – 20% reduction in Nile red fluorescence, which can likely
be interpreted as passive diffusion of Nile red from the periphery or edges of the
particles.

Figure 27. Fluorescence emission behavior observed at different time intervals for NVOC-PEtG
and BnCO-PEtG control particles with varying PLA content after the UV light irradiation (30
min).
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Figure 28. Fluorescence emission behavior observed at different time intervals for disulfidePEtG and BnCO-PEtG with varying PLA content after the addition of DTT.

In terms of controlling the release of Nile red, UV light as a stimulus did not give
significant control over the burst release. After exposure to UV light, each particle
suspension resulted in a quick burst release consistent with the corresponding PLA
content, followed by a slower rate of release from the PLA regions. There does however
appear to be some control over where the slower, plateau region occurs by varying the
wt% of PLA content in these particles. Using 7.7 mmol DTT as a stimulus led to a better
control in the burst release. The difference can be seen in the 100% PEtG sample that
took 24 h to release 80% of the Nile red compared to the UV sample that took less than 1
h to release the same amount. Due to this slower release profile, the plateau regions in the
DTT-responsive data are not as apparent.

3.5 Hydrophobic Cargo Encapsulation and Release
3.5.1

Characterization of Drug-Loaded PLA-PEtG NPs

The DLS studies, along with the Nile red studies, provided sufficient proof of concept for
triggerable degradation of PEtG NPs. The next step was to load the particles with a model
drug and test for triggerable release of this drug.86 A common literature procedure for
these studies involves encapsulating a UV active drug molecule within the DDS and
placing the particle suspensions in dialysis. Using a drug that absorbs UV or visible light
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above ~210 nm, the drug release can be tracked by taking UV-Vis spectroscopy
measurements of the dialysate or the suspension within the dialysis membrane over time
to obtain a release profile. Several hydrophobic drugs were investigated as potential
candidates for encapsulation and drug release. The loading efficiency and drug content
calculations were made for each drug and are summarized in Table 5. Surprisingly, the
four different drugs tested had starkly different loading efficiencies and drug contents.
Curcumin, an herbal supplement, showed the worst encapsulation efficiency at 21% with
a drug content of only 3%. The most successful candidate was celecoxib, an antiinflammatory medication. Celecoxib had a loading efficiency of 77% and a 25% drug
content. Letrozole, used to treat breast cancer, and DOX, a common chemotherapy, were
also tested with moderate loading efficiencies of 44% and 38% respectively. Based on the
loading efficiencies and drug content of these four candidates, letrozole and celecoxib
were chosen as the two drugs for further studies.
Table 5. Drug loading properties of 30% PLA-PEtG NPs.

Loading
Efficiency

Drug Content
(wt%)

λmax
(nm)

Letrozole

44 ± 5%

17 ± 2%

240

Celecoxib

77 ± 9%

25 ± 3%

253

Curcumin

21 ± 3%

3 ± 1%

524

Doxorubicin

38 ± 7%

22 ± 4%

485

Drug

Structure
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PLA-PEtG NPs containing letrozole were characterized using DLS and TEM to examine
any differences between loaded and unloaded particles in terms of average diameter and
morphology. In Figure 29 and Table 6 data collected for unloaded PLA-PEtG particle
diameters from DLS studies were compared with those collected for their respective
loaded counterparts. Drug-loaded particles were similar in size to unloaded particles, but
significantly larger diameters (p < 0.05) were observed for 100% PEtG, 30% PLA-PEtG,
50% PLA-PEtG and 100% PLA particles. The PDIs for the loaded particles were also
significantly larger for 30% PLA-PEtG particles. However, loaded particles were well
below the 300 nm cutoff for maximum particle diameter and the PDIs were all below 0.3,
which is the benchmark for uniformity in size.
Table 6. Size specifications of the letrozole-loaded/unloaded particles based on PLA-PEtG
blends. (Standard Error, n = 3)

Unloaded*

Loaded
DLS Z-avg.
(nm)

PDI

DLS Z-avg.
(nm)

PDI

100% PEtG

144 ± 9

0.16 ± 0.06

114 ± 9

0.19 ± 0.07

10% PLA-PEtG

137 ± 21

0.29 ± 0.10

127 ± 19

0.28 ± 0.11

30% PLA-PEtG

128 ± 16

0.22 ± 0.04

118 ± 7

0.11 ± 0.03

50% PLA-PEtG

133 ± 10

0.17 ± 0.03

122 ± 8

0.12 ± 0.03

100% PLA

138 ± 9

0.17 ± 0.04

109 ± 10

0.13 ± 0.04

Blend

*

The data recorded for unloaded particles were repeated for comparison.
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Figure 29. Representative DLS diameter distributions for each letrozole-loaded PLA-PEtG blend.
(a) volume distributions and (b) intensity distributions.

Loaded particles prepared from 100% PEtG and 50% PLA-PEtG were also examined by
TEM (Figure 30). The images show mostly spherical particles with diameters of 50–80
nm. As mentioned above, the average particle diameter in the TEM images are smaller
than those measured by DLS.

a

b

Figure 30. TEM images of letrozole-loaded (a) 100% PEtG NPs and (b) 50% PLA-PEtG NPs.
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3.5.2

Triggerable Release of Letrozole

The novelty of the PEtG system, being the rapid burst release after triggering, posed a
challenge of tracking released drug using conventional methods like dialysis. It was
observed that the particles degraded so rapidly after application of the stimuli that the
drug precipitated, leading to sedimentation within the dialysis membrane (Figure A-6a).
On the other hand, the BnCO-PEtG controls showed no precipitation or sedimentation
over the same time frame (Figure A-6b). Measurements of the dialysate were therefore
not an accurate representation of released drug. To overcome this, 200 µL samples were
taken of the contents within the dialysis membrane at incremental time points. These 200
µL samples were passed through 0.22 µm syringe filters. The resulting filtered
suspensions were then diluted with acetonitrile to dissolve the particles and remaining
encapsulated drug. The absorbance was measured at 240 nm to quantify the amount of
drug that had remained encapsulated. The study was conducted for NVOC-PLA-PEtG
NPs. BnCO-PEtG particles were used as the non-responsive control and non-irradiated
NVOC-PEtG (PLA-PEtG-nonirr.) particle samples were also measured as an additional
control. In Figure 31, the release of letrozole from each PLA-PEtG particle system is
shown. Figure 32 shows the release profiles for each of the control samples.

Figure 31. Release profile of letrozole-loaded, UV-irradiated NVOC-PEtG particles.
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Figure 32. Release profile of letrozole-loaded particle controls: BnCO-PEtG and negative
controls.

After irradiation with UV light, a significant burst release was observed with the
irradiated NVOC-PEtG particles, which was not seen in the 100% PLA sample or the
control samples. This can be attributed to successful and specific triggerable release using
UV light as a stimulus in this study. For example, the 100% NVOC-PEtG particles
released over 80% of the encapsulated letrozole over the first hour whereas the nonirradiated control retained essentially all of the encapsulated drug for more than 100 h.
The second important observation was the noticeable trend of increasing wt% PLA
leading to a plateau in drug release at increased remaining drug percentages. This is
consistent with previous DLS and Nile red studies. The only major exception to this
general trend was several of the 100% NVOC-PEtG measurements which had higher
retained drug, which could result from some particle destabilization and aggregation or
simply the sample-to-sample variability on the measurements. The third, unfavorable
observation was the relatively fast rate of release of letrozole from the control particles.
Approximately 20 – 40% of letrozole was released from all control samples except nonirradiated 100% PEtG over the period of five days. The release may arise from letrozole
partitioning gradually into the aqueous environment and diffusing out through the
dialysis membrane. The solubility of letrozole is 80 µg/mL in water. This value
multiplied by 100 mL of dialysate equates to 8 mg that can be dissolved in the dialysate.
Only 3 mg of letrozole was used in this study per sample so passive diffusion of the
controls into the dialysate is plausible.
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3.5.3

Triggerable Release of Celecoxib

To test a different stimuli-responsive end-cap in this system, particles were synthesized
using a reduction-sensitive end-cap containing a disulfide bond. The common small
triggering molecule used in these systems is DTT. Complications arose when attempting
to monitor the release of cargo from disulfide-PEtG particles using letrozole and
celecoxib due to DTT having strong absorbance character in the 200−250 nm region. The
absorbance of the stimulus gave inconsistent results in release studies by drowning out
the signal of the drug molecule, even when accounted for when running a background of
the same concentration of stimulus present. To overcome the erroneous data acquired
from background stimulus in the sample, a different approach to measuring the release
was needed. It was hypothesized that the quick release could be taken advantage of using
centrifugation. After release, the precipitated drug could be removed by centrifugation to
collect a pellet at incremental time points. The remaining particle suspension could be
decanted off and the study continued, leaving released drug as a pellet that could be
dissolved then the concentration quantitatively measured to determine the amount of
released drug. This would avoid the presence of stimulus absorbance when measuring the
UV absorbance.
Celecoxib was chosen to show versatility in potential cargo encapsulation, as well as for
its high loading efficiency and drug content. Particles were prepared as with previous
studies, including each PLA-PEtG blend, pure PEtG, pure PLA particles. The samples
were in 100 mM, pH 7.4 phosphate buffer and kept in a 37 °C oven for the duration. DTT
was used as the stimulus with a concentration of 15 mmol introduced to both the
disulfide-PEtG and BnCO-PEtG control samples. No DTT was added for separate
disulfide-PEtG samples for a negative control. At specific time points, the samples were
centrifuged and the pellet was collected. The pellet was distributed into thirds and
dissolved in 1 mL acetonitrile. At the first time point, the disulfide-PEtG samples were
instead dissolved into 1 mL d3-acetonitrile for NMR analysis. It was important to
distinguish if the pellet contained significant amounts of intact PEtG which could signify
presence of intact particles in the pellet. The samples were analyzed using UV-Vis
spectroscopy to determine the concentration of celecoxib present in the pellet. The
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release profiles for the DTT-treated particles are shown in Figure 33a. and the controls
are shown in Figure 33b.

Figure 33. Release profile of celecoxib-loaded PLA-PEtG-disulfide NPs and their controls. (a)
celecoxib-loaded, 15 mmol DTT added PLA-PEtG-disulfide particles and (b) celecoxib-loaded
particle controls: BnCO-PEtG and negative control.

The same general trend seen in the DLS and Nile red studies was observed for the release
of celecoxib. Pure PEtG particles exhibited the fastest release and with increasing PLA
content, the release is slowed. There is no significant burst release seen in this study
which is consistent with previous reduction-responsive particle studies. The controls
appear to be roughly linear in their release profile with no significant burst release. The
gradual, slow release of celecoxib in these samples is consistent across both the control
samples and the disulfide-PEtG with no added DTT samples. The release from the
controls can be attributed to slow, passive diffusion of the celecoxib out of the particles.
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It is important to note that the centrifugation method is not a perfect analysis. For
example, during centrifugation, not all of the precipitated drug goes into the pellet. There
is visible drug still suspended in the decanted solution that is not being accounted for in
the release. The small portion of drug left suspended in the sample may account for the
pure PEtG sample not reaching 100% release. The presence of free drug was a noticeable
problem with both the 100% PEtG sample and 10% PLA-PEtG sample. It is possible that
the release in these two samples is much faster than what is shown. Secondly, there is an
unavoidable small volume (~ 100 µL) of sample that remains in the centrifuge tube after
decanting. This residual volume, although small, does contain particles encapsulated with
celecoxib. It also is possible that some of the “release” depicted in the controls is actually
celecoxib that was still encapsulated within intact particles in this residual small volume.
The pellet content was also examined by NMR spectroscopy to determine qualitatively
the presence of PEtG. Stimuli-responsive samples should show very little intact PEtG
peaks and should compose mostly of celecoxib peaks and/or PLA peaks. If there exists
significant PEtG, it is possible that either particles were present in the pellet or in the
residual sample left after decanting. NMR spectra were taken for each sample at t = 4 h
and t = 24 h post-DTT treatment. The aromatic peaks of celecoxib are used as an
indicator of the presence of celecoxib. The backbone proton of PLA appears as a broad
singlet at 5.1 ppm and the backbone proton of PEtG appears as another broad singlet at
5.6 ppm. This can be examined for each sample in the celecoxib release study found in
appendix Figures A-16–A-27. The 10% PLA-PEtG-disulfide sample is depicted in Figure
34 for discussion. Coinciding with the concentration of celecoxib found by UV-vis
spectroscopy, the NMR spectrum of 10% PLA-PEtG-disulfide shows the majority of the
pellet to be celecoxib. There is very minimal intact PEtG present as can be concluded
from the absence of the proton signal in the backbone of the intact polymer. There is a
sharp singlet present at 5.7 ppm which is consistent with the hydrated version of the ethyl
glyoxylate monomer. There is also presence of PLA in the pellet which is most likely due
to the precipitated of PLA in the aqueous environment as the PEtG degrades,
destabilizing the PLA portions of the particles. The 24 h spectrum is consistent with the
UV data where a significant portion of celecoxib was not released at this time point. Each
disulfide-PEtG sample showed similar NMR spectra results, the most important result
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being the absence of intact PEtG. The BnCO-PEtG control samples as well as the
disulfide-PEtG with no DTT stimulus controls do show some intact PEtG in their spectra.

Figure 34. 1H NMR spectra of pellet collected from celecoxib release study of 10% PLA-PEtGdisulfide sample after 4 and 24 h (CD3CN, 400 MHz).

Overall, from the celecoxib release profiles, along with the NMR spectra, it can be
concluded that celecoxib could be triggered to release from the PLA-PEtG-disulfide
particles to a much higher extent than from control samples. Furthermore, increasing
PLA content led to a slower release rate over a 24 h period. These data are consistent
with the letrozole-loaded NVOC-PEtG studies, as well as, the DLS and Nile red studies.

3.6 PLA-PEtG NP Cell Viability Studies
It was important to determine how these particles behaved in vitro to ascertain
effectiveness of PLA-PEtG NPs as potential DDSs. To study their behavior in cells, MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays were conducted
on MDA-MB-231, human breast cancer cells. This assay measures the metabolic
activities of cells. In living and metabolically active cells, the MTT reagent is reduced to
a compound that can be measured spectrophotometrically. Due to the high loading
efficiency and drug content, celecoxib was chosen as the cargo molecule for these
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studies. Cells were seeded on 96-well plates for each cell viability study. Free celecoxib,
unloaded 100% NVOC-PEtG, unloaded 50% PLA-PEtG-NVOC, non-irradiated
celecoxib-loaded 100% NVOC-PEtG and non-irradiated celecoxib-loaded 50% PLAPEtG-NVOC were each administered to a seeded, 96-well plate and allowed to incubate
for 48 h to determine the cell viability for each of these controls. Untreated cells grown in
the aforementioned media, as well as a media-only control were tested. Lastly, celecoxibloaded 100% NVOC-PEtG and celecoxib-loaded 50% PLA-PEtG-NVOC were
administered to the cells. The cells were then irradiated with 30 minutes of 360 nm light
using light emitting diode flashlights.
It is hypothesized that the particles will enter the cell by the active transportation via
endocytosis and exist in vesicles inside the cell where the release of cargo can occur.
Unloaded 100% PEtG and 50% PLA-PEtG particles were studied to determine the
toxicity of the materials themselves. Neither particles showed signs of cell toxicity even
at 1 mg/mL, the highest concentration of particles evaluated (Figure 35). Free celecoxib
had a half maximal inhibitory concentration (IC50) of 79 µM which is consistent with the
literature value (Figure 36).87 For the celecoxib-loaded particles and celecoxib-loadedirradiated particles, the concentration was plotted as the log of celecoxib concentration to
compare cell viability of free celecoxib with irradiated and non-irradiated cell plates. The
concentration of celecoxib in the loaded particles was calculated based on the loaded
wt% of celecoxib within the particles multiplied by the concentration of particles
administered. These plots are shown in Figure 36 and Figure 37. From the data, several
conclusions can be made. First, the celecoxib-loaded particles were much less toxic than
the free drug. Significant cell death was only seen at the highest concentration of particles
(~ 600 μM of drug). This suggests that the free drug was not released fully within the
cells or was released over a longer time frame, leading to lower toxicity. In addition, the
UV irradiated particles showed no significant difference in toxicity relative to the nonirradiated particles. It would be expected that irradiated particles would release their
celecoxib contents and induce cell death in this manner, but this was not seen. It could be
possible that the celecoxib was precipitating out of solution once released, as seen in the
release studies. In addition, it is known known whether the particles were taken up by
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cells. This will require further investigation and other stimuli will need to be studied.
However, it is still important to conclude that PEtG NPs showed no toxicity to MDAMB-231 cells and they could decrease the celecoxib toxicity to this cell line.

Figure 35. MTT assays of unloaded 100% NVOC-PEtG and unloaded 50% PLA-PEtG-NVOC
NPs in MDA-MB-231 cells. Error bars represent the standard deviations on the measurements.
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Figure 36. MTT assay cell viability studies of free celecoxib, 100% NVOC-PEtG-loaded and
100% NVOC-PEtG-loaded irradiated with 30 minutes of UVA light in MDA-MB-231 cells.
Error bars represent the standard deviations on the measurements.
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Figure 37. MTT assay cell viability studies of free celecoxib, 50% PLA-PEtG-NVOC-loaded and
50% PLA-PEtG-NVOC-loaded irradiated with 30 minutes of UVA light in MDA-MB-231 cells.
Error bars represent the standard deviations on the measurements.
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4

Conclusions & Future Work

The results of this work led to several significant findings relevant to the use of PEtG in
DDSs. First, it was shown that PEtG can be used as hydrophobic homopolymer to
synthesize polymeric NPs using an O/W emulsion technique. 100% PEtG NPs are stable
in solution and can be synthesized with ~100 nm diameters, which is in the optimal range
for intravenous injection. These particles were demonstrated to be stimuli-responsive
when manufactured with a stimuli-responsive end-capped PEtG. These stimuliresponsive particles could be loaded with a hydrophobic cargo and triggered to release
that cargo upon introduction of relatively small concentrations of stimulus.
In addition, while pure PEtG NPs rapidly release a large fraction of their cargo in
response to stimuli, it was possible to tune the extent of this burst release using blends
with PLA. By changing the wt% PLA, it was found that the release rates of cargo
molecules can be tuned. Increasing PLA character led to a slower release of cargo. The
morphology and diameter of blended particles showed no significant difference to 100%
PEtG particles. This was confirmed by DLS and TEM.
Two stimuli-responsive end-capped PEtG NPs were studied in this work, UV light
sensitive and reduction sensitive. These two stimuli-responsive particles had interesting
differences in their release profiles. NVOC-PEtG particles showed a very rapid, burst
release within the first hour post-UV irradiation. This was followed by a plateau region
correlating to the amount of PLA present in the particles. This gave a two-part release: a
quick burst release of drug at the beginning due to rapid degradation of PEtG followed by
a slower release of drug from the remaining PLA domains. Disulfide-PEtG particles
showed less initial burst release, but still showed slower release with increasing PLA
content. These trends were seen for DLS studies, Nile red studies and hydrophobic drug
studies.
Finally, PLA-PEtG NPs showed no toxicity to MDA-MB-231 cells, even at the highest
concentration of particles evaluated (1 mg/mL). When these particles were loaded with
celecoxib, no toxicity was seen until a concentration of 600 µM. This is well above the
IC50 of celecoxib which is reported to be around 79 µM in MDA-MB-231 cells.

65

Unfortunately, it was found that celecoxib-loaded NVOC-PEtG particles administered to
this cell line did not show a decrease of cell viability when irradiated with 30 minutes of
UV light. It is not known if the nanoparticles were taken up by cells. This would require
further studies to investigate this using labeled particles. It is also possible that the
released celecoxib could be precipitating out of solution, therefore unavailable to the
cells.
To extend this work, several areas could be further investigated. First, research towards
alternative surfactants could produce PEtG particles that are less susceptible to
aggregation upon drying. This would allow for ease in drying and dispersing the particles
back into solution, increasing their shelf-life. Second, it would also be interesting to test a
library of stimuli-responsive particles by exchanging the end-cap on PEtG. This would
increase the versatility of PEtG NPs and possibly increase their potential applications.
This work tested UV and reduction-responsive particles. Particles responsive to pH or
temperature might lead to interesting applications. Lastly, further investigation into
cellular uptake is essential. Why UV-responsive, celecoxib-loaded particles irradiated
with UV light did not lead to a significant drop in cell viability remains unknown.
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Figure A-1. Letrozole calibration curve in acetonitrile ( = 240 nm,  = 30,600 L/cm·cm).
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Figure A-2. Celecoxib calibration curve in acetonitrile ( = 253 nm,  = 16,400 L/cm·cm).
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Figure A-3. TEM images of (a) pure BnCO-PEtG NPs, (b) 10 wt% PLA, (c) 30 wt% PLA, and
(d) 50 wt% PLA.
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Figure A-4. Determination of particle diameters and disparities by DLS for PLA-PEtG-BnCO
blends. (a) intensity distribution and (b) volume distribution.

Figure A-5. Determination of particle diameter and dispersity by DLS for PLA-PEtG-disulfide
blends. (a) intensity distribution and (b) volume distribution.
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Table A-1. Z-avg. and polydispersity indices for the PLA-PEtG-BnCO & disulfide blends.

Z-avg. (nm)
Blend

Z-avg. (nm)
PDI

BnCO

PDI
disulfide

0% PLA

128 ± 15

0.11 ± 0.05

129 ± 11

0.17 ± 0.07

10% PLA

144 ± 16

0.17 ± 0.06

130 ± 6

0.11 ± 0.03

30% PLA

127 ± 11

0.11 ± 0.02

122 ± 6

0.09 ± 0.01

50% PLA

131 ± 4

0.14 ± 0.02

124 ± 12

0.12 ± 0.03

Figure A-6. UV-light irradiated letrozole-containing NPs based on (a) NVOC-PEtG NPs
(containing letrozole precipitates) and (b) BnCO-PEtG control, in a dialysis membrane bags.
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a

b

Figure A-7. Celecoxib precipitates formed from celecoxib-containing NPs based on disulfidePEtG upon the addition of DTT at (a) 0 and (b) 4 h.

Figure A-8. Celecoxib precipitates formed from celecoxib-containing NPs based on PLA-PEtGdisulfide blends upon the addition of DTT after 4 h. (a) 100% PEtG, (b) 10% PLA-PEtG, (c) 30%
PLA-PEtG, and (d) 50% PLA-PEtG.
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Figure A-9. Celecoxib precipitates formed from celecoxib-containing NPs based on PLA-PEtGdisulfide blends upon the addition of DTT after 24 h. (a) 100% PEtG, (b) 10% PLA-PEtG, (c)
30% PLA-PEtG, and (d) 50% PLA-PEtG.

Figure A-10. Celecoxib precipitates formed from celecoxib-containing NPs based on BnCOPEtG control blends upon the addition of DTT after 4 h. (a) 100% PEtG, (b) 10% PLA-PEtG, (c)
30% PLA-PEtG, and (d) 50% PLA-PEtG.
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Figure A-11. Celecoxib-containing NPs based on BnCO-PEtG control blends upon the addition
of DTT after 24 h. (a) 100% PEtG, (b) 10% PLA-PEtG, (c) 30% PLA-PEtG, and (d) 50% PLAPEtG.

Figure A-12. Celecoxib-containing NPs based on PLA-PEtG-disulfide blends after 4 h. (a) 100%
PEtG, (b) 10% PLA-PEtG, (c) 30% PLA-PEtG, and (d) 50% PLA-PEtG.
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Figure A-13. Celecoxib-containing NPs based on PLA-PEtG-disulfide blends after 24 h. (a)
100% PEtG, (b) 10% PLA-PEtG, (c) 30% PLA-PEtG, and (d) 50% PLA-PEtG.

Figure A-14. 1H NMR spectrum of celecoxib (CD3CN, 400 MHz).
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Figure A-15. 1H NMR spectrum of poly(D,L-lactic acid) (CD3CN, 400 MHz).

Figure A-16. 1H NMR spectrum of disulfide-PEtG recorded during the celecoxib release studies
(CD3CN, 400 MHz).
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Figure A-17. 1H NMR spectrum of pellet collected from celecoxib release study of 100%
disulfide-PEtG sample after 4 and 24 h (CD3CN, 400 MHz).

Figure A-18. 1H NMR spectrum of pellet collected from celecoxib release study of 100%
disulfide-PEtG no DTT control sample after 4 and 24 h (CD3CN, 400 MHz).
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Figure A-19. 1H NMR spectrum of pellet collected from celecoxib release study of 100%
BnCO-PEtG control sample after 4 and 24 h (CD3CN, 400 MHz).

Figure A-20. 1H NMR spectrum of pellet collected from celecoxib release study of 10% PLAPEtG-disulfide sample after 4 and 24 h (CD3CN, 400 MHz).
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Figure A-21. 1H NMR spectrum of pellet collected from celecoxib release study of 10% PLAPEtG-disulfide no DTT control sample after 4 and 24 h (CD3CN, 400 MHz).

Figure A-22. 1H NMR spectrum of pellet collected from celecoxib release study of 10% PLAPEtG-BnCO control sample after 4 and 24 h (CD3CN, 400 MHz).
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Figure A-23. 1H NMR spectrum of pellet collected from celecoxib release study of 30% PLAPEtG-disulfide sample after 4 and 24 h (CD3CN, 400 MHz).

Figure A-24. 1H NMR spectrum of pellet collected from celecoxib release study of 30% PLAPEtG-disulfide no DTT control sample after 4 and 24 h (CD3CN, 400 MHz).
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Figure A-25. 1H NMR spectrum of pellet collected from celecoxib release study of 30% PLAPEtG-BnCO control sample after 4 and 24 h (CD3CN, 400 MHz).

Figure A-26. 1H NMR spectrum of pellet collected from celecoxib release study of 50% PLAPEtG-disulfide sample after 4 and 24 h (CD3CN, 400 MHz).
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Figure A-27. 1H NMR spectrum of pellet collected from celecoxib release study of 50% PLAPEtG-disulfide no DTT control sample after 4 and 24 h (CD3CN, 400 MHz).

Figure A-28. 1H NMR spectrum of pellet collected from celecoxib release study of 100% PLA
sample after 4 and 24 h (CD3CN, 400 MHz).
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Figure A-29. 1H NMR spectrum of NVOC-PEtG (CDCl3, 400 MHz).

Figure A-30. 1H NMR spectrum of BnCO-PEtG (CDCl3, 400 MHz).
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Figure A-31. 1H NMR spectrum of disulfide-PEtG (CD3CN, 400 MHz).
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